DDInter202 DDInter782
Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Bexarotene {u} (Compound) resembles {v} (Compound) Tamibarotene
Bexarotene {u} (Compound) treats {v} (Disease) hematologic cancer
Bexarotene {u} (Compound) binds {v} (Gene) RXRG
Bexarotene {u} (Compound) is included by {v} (Pharmacologic Class) Retinoids
Bexarotene {u} (Compound) causes {v} (Side Effect) Hypocholesterolaemia
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Griseofulvin
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palifermin
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amlodipine
Bexarotene {u} may lead to a major life threatening interaction when taken with {v} Cytarabine
Bexarotene (Compound) resembles Tamibarotene (Compound)
Bexarotene (Compound) treats hematologic cancer (Disease)
Bexarotene (Compound) binds RXRG (Gene)
Bexarotene (Compound) is included by Retinoids (Pharmacologic Class)
Bexarotene (Compound) causes Hypocholesterolaemia (Side Effect)
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Griseofulvin
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Palifermin
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine
Bexarotene may lead to a major life threatening interaction when taken with Cytarabine